Syncromune® Inc., Appoints Jonathan Lewis, M.D., Ph.D., A Renowned Immune Therapy Pioneer, as Chief Medical Officer
“SYNC-T™ for solid tumor therapy has the potential to be a game changer, much like CAR T cells have been for leukemias and lymphomas,” said Dr. Lewis.
- “SYNC-T™ for solid tumor therapy has the potential to be a game changer, much like CAR T cells have been for leukemias and lymphomas,” said Dr. Lewis.
- It is an honor, a privilege, and an exhilarating opportunity to be able to contribute to this remarkable technology and team.
- Previously, he served as the Executive Chairman, CEO, and Chief Medical Officer of Ziopharm Oncology from 2004 to 2015, where he led the development of novel immunotherapies for metastatic cancers.
- Prior to Ziopharm, Dr. Lewis held the positions of Chairman and Chief Medical Officer of Antigenics, Inc, a company focused on personalized therapeutic vaccines for cancers, infectious diseases, and autoimmune disorders.